Bone Mineral Density in Male Schizophrenia Patients: A Review

References

• Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT, Jr., Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S: Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161(8):1334–1349
   Google Scholar
• Meyer JM, Nasrallah HA eds. Medical Illness and Schizophrenia. Washington, D.C.: American Psychiatric Press, Inc., 2003
   Google Scholar
• NIH: Consensus Conference development panel on osteoporosis prevention, diagnosis and therapy. JAMA 2001; 285:785–795
   Google Scholar
• Barondess DA, Nelson DA: Schlaen SE: Whole body bone, fat, and lean mass in black and white men. J Bone Miner Res 1997; 12(6):967–971
   Google Scholar
• Wagner DR, Heyward VH: Measures of body composition in blacks and whites: A comparative review [see comment]. Am J Clini Nutr 2000; 71(6):1392–1402
   Google Scholar
• Naidoo U, Goff DC, Klibanski A: Hyperprolactinemia and bone mineral density: The potential impact of antipsychotic agents. Psychoneuroendocrinology 2003; 28(Suppl 2):97–108
   Google Scholar
• Delva NJ, Crammer JL, Jarzylo SV, Lawson JS, Owen JA, Sribney M, Weir BJ, Yendt ER: Osteopenia, pathological fractures, and increased urinary calcium excretion in schizophrenic patients with polydipsia. Biol Psychiatry 1989; 26(8):781–793
   Google Scholar
• Tannirandorn P, Epstein S: Drug-induced bone loss. Osteoporosis Intl 2000; 11(8):637–659
   Google Scholar
• Cohen O, Rais T, Lepkifker E, Vered I: Lithium carbonate therapy is not a risk factor for osteoporosis. Horm Met Res 1998; 30(9):594–597
   Google Scholar
• Fric M, Laux G: Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics. Psychiatrische Praxis 2003; 30(Suppl 2):S97–101
   Google Scholar
• Biller BM, Baum HB, Rosenthal DI, Saxe VC, Charpie PM, Klibanski A: Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea [see comments]. J Clin Endocrinol Metab 1992; 75(3):692–697
   Google Scholar
• Abraham G, Paing WW, Kaminski J, Joseph A, Kohegyi E, Josiassen RC: Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: A prospective study. Am J Psychiatry 2003; 160(9):1618–1620
   Google Scholar
• Higuchi T, Komoda T, Sugishita M, Yamazaki J, Miura M, Sakagishi Y, Yamauchi T: Certain neuroleptics reduce bone mineralization in schizophrenic patients. Neuropsychobiology 1987; 18(4):185–188
   Google Scholar
• Halbreich U, Rojansky N, Palter S, Hreshchyshyn M, Kreeger J, Bakhai Y, Rosan R: Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995; 57(5):485–491
   Google Scholar
• Abraham G, Friedman RH, Verghese C: Osteoporosis demonstrated by dual energy x-ray absorptiometry in chronic schizophrenic patients. Biol Psychiatry 1996; 40(5):430–431
   Google Scholar
• Crawford AM, Beasley CM, Jr., Tollefson GD: The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997; 26(1):41–54
   Google Scholar
• Bilici M, Cakirbay H, Guler M, Tosun M, Ulgen M, Tan U: Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int J Neurosci 2002; 112(7):817–828
   Google Scholar
• Abraham G, Halbreich U, Friedman RH, Josiassen RC: Bone mineral density and prolactin associations in patients with chronic schizophrenia [see comment]. Schizophr Res 2003; 59(1):17–18
   Google Scholar
• Becker D, Liver O, Mester R, Rapoport M, Weizman A, Weiss M: Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clini Psychiatry 2003; 64(7):761–766
   Google Scholar
• Meaney AM, O–Keane V: Reduced bone mineral density in patients with schizophrenia receiving prolactin raising antipsychotic medication. J Psychopharmacology 2003; 17(4):455–458
   Google Scholar
• Lean M, De Smedt G: Schizophrenia and osteoporosis. Int Clini Psychopharmacol 2004; 19:31–35
   Google Scholar
• Meaney AM, Smith S, Howes OD, O–Brien M, Murray RM, O–Keane V: Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004; 184:503–508
   Google Scholar
• Lehman D, Meyer JM: Decreased bone mineral density in male schizophrenia patients. Schizophr Res 2005; 76:131–133
   Google Scholar
• Combs DR, Advokat C: Antipsychotic medication and smoking prevalence in acutely hospitalized patients with chronic schizophrenia. Schizophr Res 2000; 46(2–3):129–137
   Google Scholar